We serve Chemical Name:hexadecanoic-7,7,8,8-d4 acid CAS:75736-49-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:hexadecanoic-7,7,8,8-d4 acid
CAS.NO:75736-49-1
Synonyms:[7-(3,5-dimethoxyphenyl)-7-methyloctyloxy]benzene;[7,7,8,8-2H4]-1-hexadecanoic acid;palmitic acid-7,7,8,8-d4;3,5-dimethoxy-1-(2-methyl-8-phenoxyoctan-2-yl)benzene;Benzene,1-(1,1-dimethyl-7-phenoxyheptyl)-3,5-dimethoxy
Molecular Formula:C16H28D4O2
Molecular Weight:260.44900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:37.30000
Exact Mass:260.26500
LogP:5.55230
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like [7-(3,5-dimethoxyphenyl)-7-methyloctyloxy]benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzene,1-(1,1-dimethyl-7-phenoxyheptyl)-3,5-dimethoxy physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[7,7,8,8-2H4]-1-hexadecanoic acid Use and application,3,5-dimethoxy-1-(2-methyl-8-phenoxyoctan-2-yl)benzene technical grade,usp/ep/jp grade.
Related News: The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds. hexadecanoic-7,7,8,8-d4 acid manufacturer The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. hexadecanoic-7,7,8,8-d4 acid supplier I believe they came to the right decision on behalf of the American public, Sandrock said in an interview. hexadecanoic-7,7,8,8-d4 acid vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. hexadecanoic-7,7,8,8-d4 acid factory I believe they came to the right decision on behalf of the American public, Sandrock said in an interview.
